Nanoparticle technologies for cancer therapy.

Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Handbook of experimental pharmacology 01/2010; DOI: 10.1007/978-3-642-00477-3_2
Source: PubMed

ABSTRACT Nanoparticles as drug delivery systems enable unique approaches for cancer treatment. Over the last two decades, a large number of nanoparticle delivery systems have been developed for cancer therapy, including organic and inorganic materials. Many liposomal, polymer-drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater number of nanoparticle platforms are currently in the preclinical stages of development. More recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease. In this chapter, we will review the available preclinical and clinical nanoparticle technology platforms and their impact for cancer therapy.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The design and synthesis of efficient drug delivery systems are of vital importance for medicine and healthcare. Nanocarrier-based drug delivery systems, in particular nanoparticles, have generated great excitement in the field of drug delivery since they provide new opportunities to overcome the limitations of conventional delivery methods with regards to the drugs. Silk fibroin (SF) is a naturally occurring protein polymer with several unique properties that make it a suitable material for incorporation into a variety of drug delivery vehicles capable of delivering a range of therapeutic agents. SF matrices have been shown to successfully deliver anticancer drugs, small molecules, and biomolecules. This review will provide an in-depth discussion of the development of SF nanoparticle-based drug delivery systems. Copyright © 2015. Published by Elsevier B.V.
    Journal of Controlled Release 03/2015; 206. DOI:10.1016/j.jconrel.2015.03.020 · 7.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review briefly describes the concerns of nanobiotechnology in the design and development of novel vaccines using the most known nanocarriers, including nature-made nanocarriers (such as bacterial spores, virus-like particles, exosomes, and bacteriophages), man-made nanocarriers (such as Proteosomes, liposomes, virosomes, SuperFluids, and nanobeads), and their applications in therapeutic and protective immunization, as well as their advantages and disadvantages. Here, we focus on the development of nano-based vaccines as “nanovaccines” for inducing immune systems, and the foreseeable promises and problems when compared with existing vaccines. Also, we review a potential nano-hazard for vaccines, so-called nanobacterial contamination.
    Scientia Iranica 06/2013; 54. DOI:10.1016/j.scient.2013.05.012 · 0.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of various diseases, including cancer. The unique properties of nanoparticles (NPs), such as large surface-to-volume ratio, small size, the ability to encapsulate various drugs, and tunable surface chemistry, give them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make NPs a mode of treatment potentially superior to conventional cancer therapies. This review highlights the most recent developments in cancer treatment using NPs as drug delivery vehicles, including promising opportunities in targeted and combination therapy. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Trends in Molecular Medicine 02/2015; 21(4). DOI:10.1016/j.molmed.2015.01.001 · 10.11 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014